Provided by Tiger Trade Technology Pte. Ltd.

Fortress Biotech

2.98
-0.0100-0.33%
Post-market: 2.980.00000.00%16:10 EDT
Volume:650.12K
Turnover:1.94M
Market Cap:92.49M
PE:-10.17
High:3.11
Open:3.04
Low:2.87
Close:2.99
52wk High:4.53
52wk Low:1.33
Shares:31.04M
Float Shares:23.51M
Volume Ratio:2.37
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2930
EPS(LYR):-2.6890
ROE:-205.29%
ROA:-34.25%
PB:1.66
PE(LYR):-1.11

Loading ...

BRIEF-Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Reuters
·
Oct 21, 2025

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

TIPRANKS
·
Oct 21, 2025

Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive

Simply Wall St.
·
Oct 05, 2025

Fortress Biotech: Buy Rating Affirmed Amid Strategic Developments and Financial Upside

TIPRANKS
·
Oct 01, 2025

Fortress Biotech, Urica announces Crystalys’ $205M Series A financing

TIPRANKS
·
Oct 01, 2025

US FDA declines to approve Fortress Bio and Zydus' treatment for a rare pediatric disease

Reuters
·
Oct 01, 2025

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series a Financing

THOMSON REUTERS
·
Oct 01, 2025

Press Release: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Dow Jones
·
Oct 01, 2025

Fortress Biotech Inc - Cyprium Eligible for Prv, Royalties, and $129 Mln Milestones

THOMSON REUTERS
·
Oct 01, 2025

Fortress Biotech Inc - Sentynl to Address FDA Concerns and Pursue Resubmission

THOMSON REUTERS
·
Oct 01, 2025

Fortress Biotech Inc - Crl Notes Cgmp Deficiencies at Cutx-101 Manufacturing Facility

THOMSON REUTERS
·
Oct 01, 2025

Fortress Biotech Inc - FDA Issues Complete Response Letter for Cutx-101 Nda

THOMSON REUTERS
·
Oct 01, 2025

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

GlobeNewswire
·
Oct 01, 2025

Crystalys Therapeutics launches with $205 million funding round for trials of gout drug

Reuters
·
Sep 30, 2025